Source: Federal Bureau of Investigation (FBI) State Crime Alerts (b)
BOSTON – A former executive of a global pharmaceutical company was sentenced today in federal in Boston for earning more than $250,000 by trading on material non-public information.
Dishant Gupta, 41, of Hillsborough, N.J., was sentenced by U.S. District Court Judge Julia E. Kobick to two months in prison to be followed by one year of supervised release. Gupta was also ordered to pay a fine of $20,000 and forfeiture of $260,078. In October 2024, Gupta pleaded guilty to one count of securities fraud.
Gupta worked as the Director of Strategy and Operations in the Boston office of a global pharmaceutical company (Company A). In the spring of 2022, during the course of his employment at Company A, Gupta learned that Company A was negotiating to acquire certain assets of a smaller pharmaceutical company based in Boston (Company B), including its leading cancer drug, and that Company A later agreed to acquire Company B outright.
While in possession of this material non-public information, and in violation of his fiduciary duties to Company A, Gupta acquired shares of Company B in his own and his wife’s brokerage accounts – in an effort to profit from the eventual public announcement of the transaction. Gupta purchased more than 300,000 shares of Company B over approximately two and a half months. Gupta then sold all the shares he had acquired after Company A announced the acquisition of Company B, earning more than $250,000.
The Securities and Exchange Commission filed a civil complaint against Gupta alleging violations of the securities laws.
United States Attorney Leah B. Foley and Jodi Cohen, Special Agent in Charge of the Federal Bureau of Investigations, Boston Division made the announcement. Assistant U.S. Attorney Benjamin A. Saltzman of the Securities, Financial & Cyber Fraud Unit prosecuted the case.